Prospects for immunotherapy of acute myeloid leukemia using γδ T cells

Early studies demonstrated that γδ T cells undergo oligoclonal expansion in patients with malignant disease, can infiltrate neoplastic lesions and provide immune surveillance against tumor formation in mice (1). Financial and competing interests disclosure Research on γδ T-cell immunotherapy in the authors’ laboratory is supported by the Medical Research Council, Cancer Research UK, Bayer HealthCare, Bloodwise, the King's Health Partners Research and Development Fund, British Council Newton Fund Institutional Links Award, the Experimental Cancer Medicine Centre at King's College London and by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust and King's College London. Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantation. Correia DV, Fogli M, Hudspeth K, Da Silva MG, Mavilio D, Silva-Santos B. Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells.